MCET (MultiCell Technologies) EBITDA: $-0.25 Mil (TTM As of Aug. 2015)


What is MultiCell Technologies EBITDA?

MultiCell Technologies MCET -90.00% EBITDA is $-0.25 Mil as of Aug. 2015.

MultiCell Technologies's EBITDA for the three months ended in Aug. 2015 was $-0.17 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Aug. 2015 was $-0.25 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

MultiCell Technologies's EBITDA per Share for the three months ended in Aug. 2015 was $0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Aug. 2015 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

MultiCell Technologies  (OTCPK:MCET) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


MultiCell Technologies EBITDA Related Terms


MultiCell Technologies EBITDA Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies EBITDA Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.24 -1.93 -1.35 -1.37 -0.52

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 -0.02 -0.28 0.22 -0.17

MCET vs ERGO, OPLI, GLAG: EBITDA Comparison

For the Biotechnology subindustry, MultiCell Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MultiCell Technologies EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

MultiCell Technologies's EBITDA for the fiscal year that ended in Nov. 2014 is calculated as

MultiCell Technologies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Nov. 2014, MultiCell Technologies's EBITDA was $-0.52 Mil.

MultiCell Technologies's EBITDA for the quarter that ended in Aug. 2015 is calculated as

MultiCell Technologies's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Aug. 2015, MultiCell Technologies's EBITDA was $-0.17 Mil.

EBITDA for the trailing twelve months (TTM) ended in Aug. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-0.25 Mil mean?
MultiCell Technologies (MCET) has a EBITDA of $-0.25 Mil as of Aug. 2015. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on MultiCell Technologies.
Is MultiCell Technologies' EBITDA too high?
MultiCell Technologies' current EBITDA is $-0.25 Mil.
How does MultiCell Technologies' EBITDA compare to ERGO and OPLI?
MultiCell Technologies' EBITDA of $-0.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on MultiCell Technologies. MultiCell Technologies's current EBITDA is $-0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current EBITDA of $-0.25 Mil. The current EBITDA is $-0.25 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current EBITDA is $-0.25 Mil as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.